Table 1.
Cohort description
| Full Cohort | After Propensity Matching (k=0.2, w/o replacement) | Standardized Differences* | ||||||
|---|---|---|---|---|---|---|---|---|
| Variable | Continuer | Stopper | p value | Continuer | Stopper | p value | Full Cohort | Matched Cohort |
| N | 3,104 | 1,410 | 1,394 | 1,394 | ||||
| Days on Treatment, Mean (SD) | 547 (0) | 263.35 (54.1) | <0.0001 | 547 (0) | 263.64 (54.22) | <0.0001 | 7.414 | 7.391 |
| Pre-Index Exacerbation Count, Mean (SD) | 0.65 (0.96) | 0.67 (0.96) | 0.5806 | 0.67 (0.97) | 0.66 (0.96) | 0.9843 | 0.018 | 0.001 |
| Pre-Index Severe Exacerbation Count Mean (SD) | 0.18 (0.53) | 0.19 (0.52) | 0.599 | 0.21 (0.58) | 0.19 (0.51) | 0.3325 | 0.017 | 0.037 |
| Age, Mean (SD) | 47.48 (17.03) | 52.38 (17.37) | <0.000 1 | 52.03 (17.64) | 52.32 (17.42) | 0.6571 | 0.285 | 0.017 |
| Age Group | ||||||||
| 0–17 | 242 (7.8) | 65 (4.6) | <0.000 1 | 84 (6) | 65 (4.7) | 0.2774 | 0.132 | 0.061 |
| 18–64 | 2,399 (77.3) | 945 (67) | 919 (65.9) | 934 (67) | 0.231 | 0.023 | ||
| 65+ | 463 (14.9) | 400 (28.4) | 391 (28) | 395 (28.3) | 0.331 | 0.006 | ||
| Sex | ||||||||
| Female | 1,902 (61.3) | 860 (61) | 0.8566 | 852 (61.1) | 850 (61) | 0.9381 | 0.006 | 0.003 |
| Male | 1,202 (38.7) | 550 (39) | 542 (38.9) | 544 (39) | 0.006 | 0.003 | ||
| Race | ||||||||
| Unknown/Missing | 127 (4.1) | 88 (6.2) | 0.0025 | 74 (5.3) | 79 (5.7) | 0.9556 | 0.097 | 0.016 |
| Asian | 104 (3.4) | 53 (3.8) | 54 (3.9) | 53 (3.8) | 0.022 | 0.004 | ||
| Black | 291 (9.4) | 159 (11.3) | 157 (11.3) | 159 (11.4) | 0.063 | 0.005 | ||
| Hispanic | 245 (7.9) | 115 (8.2) | 106 (7.6) | 115 (8.2) | 0.010 | 0.024 | ||
| White | 2,337 (75.3) | 995 (70.6) | 1,003 (72) | 988 (70.9) | 0.106 | 0.024 | ||
| Region | ||||||||
| Midwest | 796 (25.6) | 301 (21.3) | 0.0039 | 310 (22.2) | 300 (21.5) | 0.6591 | 0.101 | 0.017 |
| Northeast | 354 (11.4) | 174 (12.3) | 151 (10.8) | 171 (12.3) | 0.029 | 0.045 | ||
| South | 1,460 (47) | 728 (51.6) | 709 (50.9) | 719 (51.6) | 0.092 | 0.014 | ||
| West | 492 (15.9) | 204 (14.5) | 222 (15.9) | 202 (14.5) | 0.039 | 0.040 | ||
| Insurance | ||||||||
| Commercial | 2,550 (82.2) | 862 (61.1) | <0.000 1 | 878 (63) | 861 (61.8) | 0.5063 | 0.480 | 0.025 |
| MedicareAdvantage | 554 (17.8) | 548 (38.9) | 516 (37) | 533 (38.2) | 0.480 | 0.025 | ||
| Household Income | ||||||||
| <$40,000 | 420 (13.5) | 277 (19.6) | <0.000 1 | 268 (19.2) | 274 (19.7) | 0.7764 | 0.165 | 0.011 |
| $40,000-$74,999 | 632 (20.4) | 316 (22.4) | 337 (24.2) | 314 (22.5) | 0.050 | 0.039 | ||
| $75,000–124,999 | 766 (24.7) | 333 (23.6) | 314 (22.5) | 333 (23.9) | 0.025 | 0.032 | ||
| $125,000$199,999 | 534 (17.2) | 158 (11.2) | 170 (12.2) | 158 (11.3) | 0.172 | 0.027 | ||
| $200,000+ | 428 (13.8) | 135 (9.6) | 139 (10) | 135 (9.7) | 0.131 | 0.010 | ||
| Unknown/Missing | 324 (10.4) | 191 (13.5) | 166 (11.9) | 180 (12.9) | 0.096 | 0.030 | ||
| Allergist/Pulmonologist visit | 2,542 (81.9) | 1,198 (85) | 0.0112 | 1,172 (84.1) | 1,183 (84.9) | 0.5652 | 0.083 | 0.022 |
| Charlson Conditions** | ||||||||
| 0–1 | 2,416 (77.8) | 973 (69) | <0.000 1 | 986 (70.7) | 970 (69.6) | 0.8031 | 0.201 | 0.025 |
| 2–3 | 510 (16.4) | 302 (21.4) | 281 (20.2) | 292 (20.9) | 0.128 | 0.020 | ||
| 4+ | 178 (5.7) | 135 (9.6) | 127 (9.1) | 132 (9.5) |
0.145 | 0.012 | ||
| Baseline Comorbidities | ||||||||
| Chronic Urticaria | 302 (9.7) | 155 (11) | 0.1921 | 145 (10.4) | 152 (10.9) | 0.6674 | 0.041 | 0.016 |
| Atopic Dermatitis | 747 (24.1) | 277 (19.6) | 0.001 | 284 (20.4) | 277 (19.9) | 0.7409 | 0.107 | 0.013 |
| GERD | 1,368 (44.1) | 627 (44.5) | 0.8039 | 631 (45.3) | 626 (44.9) | 0.8491 | 0.008 | 0.007 |
| Rhinitis | 2,493 (80.3) | 1,063 (75.4) | 0.0002 | 1,039 (74.5) | 1,056 (75.8) | 0.4563 | 0.119 | 0.028 |
| Sinusitis | 1,938 (62.4) | 789 (56) | <0.000 1 | 789 (56.6) | 784 (56.2) | 0.8485 | 0.132 | 0.007 |
| COPD | 929 (29.9) | 536 (38) | <0.000 1 | 513 (36.8) | 526 (37.7) | 0.6106 | 0.171 | 0.019 |
| Depression | 828 (26.7) | 426 (30.2) | 0.0139 | 415 (29.8) | 418 (30) | 0.9012 | 0.078 | 0.005 |
| Number of Reliever Fills in 6 months pre, Mean (SD) | 2.09 (2.82) | 2.31 (3.07) | 0.0206 | 2.24 (3.01) | 2.28 (3.05) | 0.6709 | 0.073 | 0.016 |
| ICS/LABA MPR in 6 months pre index, Mean (SD) | 0.37 (0.37) | 0.37 (0.37) | 0.9701 | 0.36 (0.37) | 0.37 (0.37) | 0.9027 | 0.001 | 0.005 |
| Response to biologic (% reducing exacerbations by 50% after 6 months biologic use) | 861 (27.7) |
474 (33.6) | <0.000 1 | 387 (27.8) | 468 (33.6) | 0.0009 | 0.128 | 0.126 |
| Response to biologic (% reducing severe exacerbations by 50% after 6 months biologic use) | 361 (11.6) | 165 (11.7) | 0.9443 | 181 (13) | 164 (11.8) | 0.3282 | 0.002 | 0.037 |
*
Standardized differences are commonly provided to quantify the success of propensity score matching in reducing differences between two cohorts. The standardized difference is the mean difference divided by its standard deviation.
**
Analyses included binary indicator variables for each Charlson condition. Proportions with each condition are reported in Supplemental Table E1.